Skip Navigation

Cardiovascular Research 2002 53(2):487-495; doi:10.1016/S0008-6363(01)00469-2
© 2002 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by d'Uscio, L. V
Right arrow Articles by Lüscher, T. F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by d'Uscio, L. V
Right arrow Articles by Lüscher, T. F
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2001, European Society of Cardiology

Chronic ETA receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice

Livius V d'Uscioa,1, Matthias Bartonc,1, Sidney Shawb and Thomas F Lüschera,*

aCardiovascular Research, Institute of Physiology, University of Zürich and Cardiology and University Hospital, Zürich, Switzerland
bDepartment of Clinical Research, University Hospital, Bern, Switzerland
cClinical Atherosclerosis and Genetic Research Laboratory, University Hospital Zurich, Zurich, Switzerland

* Corresponding author. University Hospital Zürich, Rämistrasse 100 CH-8091, Zürich, Switzerland. Tel.: +41-1-255-2121/2177; fax: +41-1-255-4251 cardiotfl{at}gmx.ch

Objective: This study investigated whether endothelial dysfunction occurs in mesenteric arteries of apoE-deficient mice and determined the role of endothelin (ET)-1, which is increased in human atherosclerosis, using an orally active endothelin ETA receptor antagonist. Methods: ApoE-deficient and C57BL/6J control mice were fed for 30 weeks with normal chow or high-fat Western-type diet alone or in combination with darusentan (LU135252; 50 mg/kg/day). Vasomotor reactivity of isolated small mesenteric arteries (I.D. 200–250 µm) was studied in vitro under perfused and pressurized conditions. Results: In both mouse strains, about one fourth of the endothelium-dependent relaxant response to acetylcholine was insensitive to inhibition by L-NAME and indomethacin. In mesenteric arteries of apoE-deficient mice on Western-type diet, increased intima-media thickness and levels of endothelin-1 protein were observed. In addition, NO-mediated endothelium-dependent relaxation to acetylcholine was reduced without affecting L-NAME/indomethacin insensitive relaxation and contractions to endothelin-1 and serotonin were enhanced. Treatment with darusentan normalized vascular structure, NO-mediated relaxation to acetylcholine and contractions to endothelin-1 and serotonin without affecting blood pressure or plasma cholesterol levels. Conclusions: Severe hypercholesterolemia in apoE-deficient mice is associated with attenuation of NO-mediated relaxation to acetylcholine and increased vascular endothelin-1 content. Chronic ETA receptor blockade may provide a new therapeutic approach to improve NO-mediated endothelium-dependent vasomotion in small arteries.

KEYWORDS Endothelins; Endothelial receptors; Endothelial function; Lipoproteins; Nitric oxide


1 The first two authors contributed equally to this work.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Lipid Res.Home page
P. Martinez-Miguel, V. Raoch, C. Zaragoza, J. M. Valdivielso, M. Rodriguez-Puyol, D. Rodriguez-Puyol, and S. Lopez-Ongil
Endothelin-converting enzyme-1 increases in atherosclerotic mice: potential role of oxidized low density lipoproteins
J. Lipid Res., March 1, 2009; 50(3): 364 - 375.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
N. Dhaun, J. Goddard, D. E. Kohan, D. M. Pollock, E. L. Schiffrin, and D. J. Webb
Role of Endothelin-1 in Clinical Hypertension: 20 Years On
Hypertension, September 1, 2008; 52(3): 452 - 459.
[Full Text] [PDF]


Home page
HypertensionHome page
R. M.P. Arruda, V. A. Peotta, S. S. Meyrelles, and E. C. Vasquez
Evaluation of Vascular Function in Apolipoprotein E Knockout Mice With Angiotensin-Dependent Renovascular Hypertension
Hypertension, October 1, 2005; 46(4): 932 - 936.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Goddard, N. R. Johnston, M. F. Hand, A. D. Cumming, T. J. Rabelink, A. J. Rankin, and D. J. Webb
Endothelin-A Receptor Antagonism Reduces Blood Pressure and Increases Renal Blood Flow in Hypertensive Patients With Chronic Renal Failure: A Comparison of Selective and Combined Endothelin Receptor Blockade
Circulation, March 9, 2004; 109(9): 1186 - 1193.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.